Medtronic (MDT) recently launched the iPro2 Professional CGM, a continuous glucose monitoring (CGM) system in 49 countries around the world. The iPro2 Professional CGM is an advanced fourth generation CGM system providing an easier way to assess glucose control not possible with standard glucose assessment methods. It allows measurement of high and low glucose fluctuations, which may not be detected with traditional tests.
Medtronic’s iPro2 Professional CGM has already received CE Mark approval. The company has filed for approval with the US Food and Drug Administration (FDA). Medtronic plans to market the iPro2 Professional CGM in 22 additional countries, including the US, taking the total to 71 countries.
Medtronic’s iPro2 Professional CGM utilizes a small glucose sensor that is capable of recording up to 288 glucose readings over 24 hours. This CGM system ensures ease of use for both clinicians and patients. Physicians can access the associated software from remote computers with an Internet connection. It also provides reports that are expected to educate patients on therapy and changes in lifestyle.
Medtronic derives its revenues from seven divisions: Cardiac Rhythm Disease Management (CRDM), Spinal, CardioVascular (CV, combined Cardiac Surgery and Vascular segments), Neuromodulation, Diabetes, Spinal/ENT, and Physio-Control. The Diabetes segment of the company is a leader in advanced diabetes care, including integrated diabetes management systems and CGM system.
We currently have a Neutral rating on Medtronic.
Medtronic’s iPro2 Professional CGM has already received CE Mark approval. The company has filed for approval with the US Food and Drug Administration (FDA). Medtronic plans to market the iPro2 Professional CGM in 22 additional countries, including the US, taking the total to 71 countries.
Medtronic’s iPro2 Professional CGM utilizes a small glucose sensor that is capable of recording up to 288 glucose readings over 24 hours. This CGM system ensures ease of use for both clinicians and patients. Physicians can access the associated software from remote computers with an Internet connection. It also provides reports that are expected to educate patients on therapy and changes in lifestyle.
Medtronic derives its revenues from seven divisions: Cardiac Rhythm Disease Management (CRDM), Spinal, CardioVascular (CV, combined Cardiac Surgery and Vascular segments), Neuromodulation, Diabetes, Spinal/ENT, and Physio-Control. The Diabetes segment of the company is a leader in advanced diabetes care, including integrated diabetes management systems and CGM system.
We currently have a Neutral rating on Medtronic.
Read the full analyst report on “MTD”
Zacks Investment Research
